Replies to post #391 on Biotech Values

[DewDiligence]

Re: $10 price targets:

>> If we consider the true value of squalamine for AMD which DEW has already suggested based on EYET, and then consider other indications (cancers) for which squalamine appears to be a good candidate, then add IL-9 opportunities for respiratory indications, how can a companies like Fortis and Caris project a valuation of only $10/share?

rwwine: I would not take these price targets too seriously. What Fortis and Caris are saying is that GENR should be trading for at least $10 in the relatively near future, but this does not imply that Fortis and Caris think GENR’s underlying value is limited to $10.